However, as indicated in the studies presented below, the cytoprotective form of autophagy appears to be the exclusive form observed in response to androgen deprivation therapies in preclinical models of prostate cancer (Figure 1), suggesting that autophagy modulation or targeting could be an effective strategy to increase the effectiveness of androgen receptor antagonists [33,34]. This evidence concerns the gene AR and prostate carcinoma.